



(51) International Patent Classification:

C07H 19/06 (2006.01) C07H 21/02 (2006.01)

C07F 9/6558 (2006.01) A61P 43/00 (2006.01)

(21) International Application Number:

PCT/US2022/044377

(22) International Filing Date:

22 September 2022 (22.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/246,870 22 September 2021 (22.09.2021) US

(71) Applicant: **SANEGENE BIO USA INC.** [US/US]; 1 Broadway, FL 14, Cambridge, Massachusetts 02142 (US).(72) Inventors: **WANG, Weiming**; 1 Broadway, FL 14, Cambridge, Massachusetts 02142 (US). **CAI, Xiaochuan**; 1 Broadway, FL 14, Cambridge, Massachusetts 02142 (US).(74) Agent: **CHEN, Chen et al.**; 1299 Pennsylvania Ave., NW Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: 2'-ALKYL OR 3'-ALKYL MODIFIED RIBOSE DERIVATIVES FOR USE IN THE IN-VIVO DELIVERY OF OLIGONUCLEOTIDES




FIG. 1

(57) **Abstract:** The present disclosure provides to linker compounds of Formula (I) or (II); pharmaceutically acceptable salts thereof, and related scaffolds and conjugates. More specifically, compounds of formula (I-A) are disclosed. The present disclosure also relates to uses of the linker compounds, scaffolds, and conjugates, e.g., in delivering nucleic acid and/or treating or preventing diseases.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*